1320TiP The efficacy and safety of stereotactic body radiation therapy (SBRT) plus toripalimab with or without bevacizumab as second-line treatment for advanced non-small cell lung cancer (NSCLC): A prospective, multicenter, open-label, phase II study

SBRT is an effective and noninvasive treatment, which achieves superior local control and survival. Combined with immune checkpoint inhibitors (ICIs), SBRT may not only amplify the in situ vaccination effect but also reprogram tumor microenvironment and improve systemic response to immunotherapy by abscopal effect. Meanwhile, bevacizumab can relieve immune suppression by activating dendritic cells (DCs) and inhibiting the activity of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs).